MannKind Corporation (MNKD) Stock Score, Valuation & Financial Research
MannKind Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for MNKD
MannKind Corporation currently has a Wall Street Score of 23/100. The stored market price is $3.55. Its financial score is 19/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What MannKind Corporation does
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells fr
MNKD financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $3.55
- Market capitalization:
- $1.13B
- Revenue:
- $360.8M
- Net income:
- $-23.9M
- Free cash flow:
- $13.7M
- Cash:
- $52.8M
- Total debt:
- $436.7M
- EPS:
- 0.02
- P/E ratio:
- 177.5x
- Financial score:
- 19/100
- Valuation score:
- 0/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $13.7M, showing positive cash generation.
- The balance sheet shows $52.8M of cash versus $436.7M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MNKD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.